Merck

We aspire to be the premier research-intensive biopharmaceutical company. Intended for U.S. residents only.
FLS:

[Merck @Merck]

We’re pleased to announce the FDA has accepted our filing related to #RSV disease. Learn more: https://t.co/DynIWTtyIK

[Merck @Merck]

Join us today at 9 a.m. ET to learn more about our Q2 2026 #earnings: https://t.co/sXhWeBrdaK $MRK

[Merck @Merck]

Our Q2 2026 #earnings results are live: https://t.co/B1yPXVRAzP

Swipe below for perspective from Chairman and CEO Rob Davis. $MRK

[Merck @Merck]

@MorningGlo14870 The safety of our products is very important to us. We’d like to hear more from you. Please contact the National Service Center at [email protected] or 1.800.672.6372

[Merck @Merck]

Today we announced our initial post-approval access plans for our investigational HIV pre-exposure prophylaxis (PrEP). We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can quickly reach those who need it in low- and middle-income countries.

Learn more: https://t.co/VxChqpc5za

[Merck @Merck]

We’re presenting new data at AIDS 2026, in collaboration with @GileadSciences, from our Phase 3 trials of an investigational, once-weekly oral #HIV treatment for adults with virologically suppressed HIV.

Learn more: https://t.co/Pc3JLyVGRY

[Merck @Merck]

@Gimpie2 Hi Gerry. For questions about our products, please contact our National Service Center at [email protected]  or 1.800.672.6372.

[Merck @Merck]

Today, we’re proud to announce the U.S. FDA approved the first oral PCSK9 inhibitor, providing a new treatment option as an adjunct to diet and exercise for adults living with #hypercholesterolemia, or high LDL cholesterol (LDL-C). Learn more about our approval here: https://t.co/ZCZLLZyK65

[Merck @Merck]

We’re excited to join the global HIV community at AIDS2026 to share new #HIV research. Learn more: https://t.co/WWzyh86wQN

[Merck @Merck]

Today, we shared positive Phase 3 topline results in certain patients with advanced or recurrent #EndometrialCancer. These findings mark an important step forward as we work to advance new treatment options for these patients. Learn more: https://t.co/uHvX8IhPSC

[Merck @Merck]

Today, we announced the #FDA has approved two new treatments for certain patients with muscle-invasive #BladderCancer, expanding options for these patients. Learn more: https://t.co/5KgVL4E2B5

[Merck @Merck]

Today, we announced an agreement with the AIDS Crisis Task Force to provide increased access to #HIV treatment for eligible people living with HIV through state AIDS Drug Assistance Programs (ADAPs). Learn more: https://t.co/L79oiltix5

[Merck @Merck]

We’re proud to announce the #FDA approvals of two new immunotherapy-based treatment combinations for certain adults with advanced triple negative breast cancer (#TNBC). This milestone, in collaboration with @GileadSciences, is an important step forward in care for patients with this disease.

Learn more: https://t.co/hToovMWycp

[Merck @Merck]

Today, the European Commission approved a new treatment combination for certain patients with muscle-invasive #BladderCancer (MIBC). Together with Pfizer and Astellas Pharma, we’re proud to provide a treatment poised to address an important unmet need for these patients. Learn more: https://t.co/troFWouubG

[Merck @Merck]

Today, we shared positive topline results from a Phase 3 induction-only study in patients with moderately to severely active ulcerative colitis. These results reinforce our ongoing commitment to advancing immunology research. Learn more: https://t.co/6wAoqcoQhq

[Merck @Merck]

Today, we announced the FDA approval of an expanded indication that helps protect certain children and adolescents at increased risk for #pneumococcal disease. Learn more: https://t.co/ZxKzil6CIA

[Merck @Merck]

We're proud of today’s #FDA approval of new combination options for certain patients with earlier-stage #kidneycancer, who may face the possibility of their kidney cancer recurring after surgery. Learn more: https://t.co/rVNKqUj8qQ

[Merck @Merck]

In collaboration with @GileadSciences, we’re excited to announce positive topline Phase 3 results for our investigational once-weekly #HIV treatment for adults with virologically suppressed HIV: https://t.co/jVRzfai8Hp

[Merck @Merck]

Click here for our latest oncology news: https://t.co/HTgbhyVNPh

[Merck @Merck]

Today at #ASCO26, in collaboration with @moderna_tx, we're proud to present five-year follow-up results from a Phase 2b study evaluating our investigational individualized neoantigen therapy for #melanoma. Learn more: https://t.co/ArMtq1C10C